Study of Dalotuzumab Alone and With Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-062 AM1)
Status:
Completed
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
This is a study of dalotuzumab given as monotherapy and in combination with ridaforolimus for
pediatric participants with advanced solid tumors. This study will have three parts. Part 1
will find a maximum tolerated dose (MTD) and collect pharmacokinetic (PK) data for
dalotuzumab alone. Part 2 will find an MTD and collect PK data for dalotuzumab in combination
with ridaforolimus. Part 3 will be an expansion cohort at the recommended Phase 2 dose (RPTD)
found in Part 2 to confirm the RPTD and look at the potential efficacy of the combination
therapy.